Intimation on loss of share certificate under Regulation 39(3) of the SEBI(LODR) Regulations is submitted

The press release shared by the Promoter Entity is submitted.

The Annual Secretarial Compliance Report issued by Mrs. V.Vasumathy, Practising Company Secretary, under Regulation 24-A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We confirm having submitted the information in XBRL also is submitted.

We wish to inform that the Board of Directors of the Company at its meeting held today i.e. on Wednesday, May 04, 2022, commenced at 11.30 a.m. and concluded at 01.40 p.m. inter alia, considered and approved the following: i)The Audited Financial Results of the Company for the year ended 31st March 2022 and reviewed financial results for the quarter ended 31st March 2022. Copy of the same is enclosed along with the Reports of the Statutory Auditors thereon and a declaration by the Chief Financial Officer of the Company that the said Reports of Statutory Auditors are with unmodified opinion. ii) Recommended a dividend of Rs. 3/- per equity share of Rs.10/- each fully paid-up, (30%) for the financial year 2021-22 subject to approval of the Members at the ensuing Annual General Meeting. The Dividend shall be paid/ dividend warrant shall be dispatched to the Shareholders within 30 days of its declaration by the Shareholders at the ensuing Annual General Meeting.

We wish to inform that the Board of Directors of the Company at its meeting held today i.e. on Wednesday, May 04, 2022, commenced at 11.30 a.m. and concluded at 01.40 p.m. inter alia, considered and approved the following: i) The Audited Financial Results of the Company for the year ended 31st March 2022 and reviewed financial results for the quarter ended 31st March 2022. Copy of the same is enclosed along with the Reports of the Statutory Auditors thereon and a declaration by the Chief Financial Officer of the Company that the said Reports of Statutory Auditors are with unmodified opinion. ii) Recommended a dividend of Rs. 3/- per equity share of Rs.10/- each fully paid-up, (30%) for the financial year 2021-22 subject to approval of the Members at the ensuing Annual General Meeting. The Dividend shall be paid/ dividend warrant shall be dispatched to the Shareholders within 30 days of its declaration by the Shareholders at the ensuing Annual General Meeting.

We wish to inform that the Board of Directors of the Company at its meeting held today i.e. on Wednesday, May 04, 2022, commenced at 11.30 a.m. and concluded at 01.40 p.m. inter alia, considered and approved the following: i) Audited Financial Results: The Audited Financial Results of the Company for the year ended 31st March 2022 and reviewed financial results for the quarter ended 31st March 2022. Copy of the same is enclosed along with the Reports of the Statutory Auditors thereon and a declaration by the Chief Financial Officer of the Company that the said Reports of Statutory Auditors are with unmodified opinion. ii) Dividend: Recommended a dividend of Rs. 3/- per equity share of Rs.10/- each fully paid-up, (30%) for the financial year 2021-22 subject to approval of the Members at the ensuing Annual General Meeting.

Compliance under Regulation 39(3) on issue of duplicate share certificate is submitted.

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for IDBI Trusteeship Services Ltd

DR.AGARWALS EYE HOSPITAL LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/05/2022 ,inter alia, to consider and approve NOTICE is hereby given pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, 4th May 2022 inter alia, to consider the Audited Financial Results of the Company for the quarter and year ended 31st March 2022 and recommendation of Dividend, if any for FY 2021-22. As intimated earlier, in terms of the Company''s Code of Internal Procedures and Conduct for Prohibition of Insider Trading, the Trading Window will remain closed until 48 hours after the announcement of the aforesaid financial results. This is for your information and records.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 26, 2022 for Dr. Agarwals Healthcare Ltd